Paul E. Marik

From Wikipedia, the free encyclopedia

Paul Ellis Marik (26 March 1958)[1] is a professor of medicine and serves as Chief, Division of Pulmonary and Critical Care Medicine at Eastern Virginia Medical School. His research interest include sepsis and tissue oxygenation.[2] According to El Mundo, Marik is a physician who specializes in lungs.[3] Marik has called himself a "status quo destabilizer".[4]

Marik was born in Johannesburg, South Africa.[5] He received his medical degree from the University of the Witwatersrand, Johannesburg, South Africa.[6]

In 2001 Marik was author of the book Handbook of Evidence Based Critical Care published by Springer-Verlag. It received positive reviews.[7] From 2002 to 2006 Marik was part of the Editorial Board of Chest journal.[8]

In 2005 Marik was named Director at the Division Pulmonary and Critical Care at Jefferson Medical College (JMC) and Thomas Jefferson University Hospital.[9]

In 2011, an international committee assembled by the main thoracic and respiratory national societies, published the Guidelines for the diagnosis and management of idiopathic pulmonary fibrosis. The guidelines's section on the treatment of complications relied in part on the results of Marik's 2001 research on the association of gastric reflux and aspiration.[10]

In 2012, an international committee updated the Guidelines for the management of severe sepsis and septic shock. In its section of supportive therapy recommendations, the committee based its concept on blood product administrations partly on research performed by Marik and W. Sibbald in 1993.[11]

Marik is inventor of the "Marik protocol", also known as the "HAT" protocol which proposes a combination of hydrocortisone, vitamin C, and thiamine as a treatment for preventing sepsis for people in intensive care. Marik's own initial research, published in 2017,[12] showed a dramatic evidence of benefit, leading to the protocol becoming popular among intensive care physicians, especially after the protocol received attention on social media and National Public Radio,[13] drawing criticism of science by press conference from the wider medical community.[14] Subsequent independent research failed to replicate Marik's positive results, indicating the possibility that they had been compromised by bias.[4] A systematic review of trials in 2021 found that the claimed benefits of the protocol could not be confirmed.[15]

Marik was lead author of a journal article on the efficacy of ivermectin as a COVID-19 treatment, which had been provisionally accepted for publication by a Frontiers Media journal in early 2021, but which was subsequently rejected on account of what the publisher said were "a series of strong, unsupported claims based on studies with insufficient statistical significance" meaning that the article did "not offer an objective [or] balanced scientific contribution to the evaluation of ivermectin as a potential treatment for COVID-19".[16]

In March 2021, Marik was reprimanded by the and ordered to complete additional education in prescribing practices after it was found he had prescribed drugs, including phenobarbital, oxycodone, tramadol, alprazolam, and diazepam, to people who were not his patients.[17][18]

Marik has written over 450 peer reviewed journal articles.[19]

References[]

  1. ^ "Paul Ellis Marik - Curriculum Vitae" (PDF). Eastern Virginia Medical School. Retrieved 21 July 2021.
  2. ^ (PDF) https://www.jefferson.edu/content/dam/tju/JeffNews/documents/2005/2005-04.pdf. Missing or empty |title= (help)
  3. ^ "Los cinco de la ivermectina, el antiparasitario contra el Covid por el que hasta se censura". ELMUNDO (in Spanish). El Mundo. 24 June 2021.
  4. ^ Jump up to: a b Rubin R (July 2019). "Wide Interest in a Vitamin C Drug Cocktail for Sepsis Despite Lagging Evidence". JAMA. 322 (4): 291–293. doi:10.1001/jama.2019.7936. PMID 31268477.
  5. ^ "Doctor who discovered Ivermectin use for Covid-19 was born in SA, studied at Wits".
  6. ^ "Biography - Dr. Paul E.Marik". benthamscience.com.
  7. ^ "Handbook of Evidence-Based Critical Care" (PDF). Respiratory Care. 48 (6). June 2003.
  8. ^ "New CHEST Editorial Board Members" (pdf). Chest. 122 (1): 13. July 2002. doi:10.1378/chest.122.1.13.
  9. ^ "https://www.jefferson.edu/content/dam/tju/JeffNews/documents/2005/2005-04.pdf" (PDF). jeffNews. Thomas Jefferson University. Retrieved 26 July 2021. External link in |title= (help)
  10. ^ Raghu, Ganesh; Collard, Harold R.; Egan, Jim J.; Martinez, Fernando J.; Behr, Juergen; Brown, Kevin K.; Colby, Thomas V.; Cordier, Jean-François; Flaherty, Kevin R.; Lasky, Joseph A.; Lynch, David A.; Ryu, Jay H.; Swigris, Jeffrey J.; Wells, Athol U.; Ancochea, Julio; Bouros, Demosthenes; Carvalho, Carlos; Costabel, Ulrich; Ebina, Masahito; Hansell, David M.; Johkoh, Takeshi; Kim, Dong Soon; King, Talmadge E.; Kondoh, Yasuhiro; Myers, Jeffrey; Müller, Nestor L.; Nicholson, Andrew G.; Richeldi, Luca; Selman, Moisés; Dudden, Rosalind F.; Griss, Barbara S.; Protzko, Shandra L.; Schünemann, Holger J. (15 March 2011). "An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management". American Journal of Respiratory and Critical Care Medicine. 183 (6): 788–824. doi:10.1164/rccm.2009-040GL. PMC 5450933. PMID 21471066.
  11. ^ Dellinger, R. P.; Levy, Mitchell M.; Rhodes, Andrew; Annane, Djillali; Gerlach, Herwig; Opal, Steven M.; Sevransky, Jonathan E.; Sprung, Charles L.; Douglas, Ivor S.; Jaeschke, Roman; Osborn, Tiffany M.; Nunnally, Mark E.; Townsend, Sean R.; Reinhart, Konrad; Kleinpell, Ruth M.; Angus, Derek C.; Deutschman, Clifford S.; Machado, Flavia R.; Rubenfeld, Gordon D.; Webb, Steven; Beale, Richard J.; Vincent, Jean-Louis; Moreno, Rui (February 2013). "Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012". Intensive Care Medicine. 39 (2): 165–228. doi:10.1007/s00134-012-2769-8. PMC 7095153. PMID 23361625.
  12. ^ Marik, Paul E.; Khangoora, Vikramjit; Rivera, Racquel; Hooper, Michael H.; Catravas, John (2017). "Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock". Chest. Elsevier BV. 151 (6): 1229–1238. doi:10.1016/j.Chest.2016.11.036. ISSN 0012-3692. PMID 27940189. S2CID 3509326.
  13. ^ "The Marik Protocol: Have We Found a "Cure" for Severe Sepsis and Septic Shock? - Emergency Medicine Blog". REBEL EM - Emergency Medicine Blog. 2017-04-07. Retrieved 2021-07-22.
  14. ^ ""Ethically and morally unacceptable": Reaction to vitamin C for sepsis trial". Dietary supplements, Nutraceuticals, Functional foods, Health ingredients, Herbals. 2020-01-28. Retrieved 2021-07-22.
  15. ^ Lee YR, Vo K, Varughese JT (May 2021). "Benefits of combination therapy of hydrocortisone, ascorbic acid and thiamine in sepsis and septic shock: A systematic review". Nutr Health: 2601060211018371. doi:10.1177/02601060211018371. PMID 34039089. S2CID 235215735.
  16. ^ Offord C (2 March 2021). "Frontiers Removes Controversial Ivermectin Paper Pre-Publication". The Scientist.
  17. ^ Adrienne Mayfield (19 May 2021). "EVMS professor reprimanded by Virginia Board of Medicine". WAVY-TV.
  18. ^ "Case Number 203034" (PDF). Virginia Board of Medicine. 16 March 2021.
  19. ^ "Paul Ellis Marik - Editorial Board - Pharmacology & Therapeutics - Journal - Elsevier". journals.elsevier.com. Elsevier. Retrieved 13 August 2021.


Flag of United StatesScientist icon Rod of Asclepius2.svg

This biographical article related to a physician in the United States is a stub. You can help Wikipedia by .

  • v
  • t
Retrieved from ""